Vera Therapeutics, Inc. Class A (VERA) Dividend History

Company News

• Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Vera Therapeutics, a late-stage biotechnology company, announced the grant of stock options and restricted stock units to 17 new employees as an inducement to their employment. The grants are part of the company's Inducement Plan and are subject to vesting conditions.

  GlobeNewswire Inc.
• Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

  Vera Therapeutics, a late-stage biotechnology company, announced plans to raise $300 million through a public offering of its Class A common stock. The company is developing treatments for serious immunological diseases, including IgAN and lupus nephritis.

  GlobeNewswire Inc.
• Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

  Vera Therapeutics announced positive long-term results from its Phase 2b study of atacicept in immunoglobulin A nephropathy (IgAN), showing stabilized kidney function through 96 weeks. The data supports atacicept's potential to modify the disease and prevent kidney failure in IgAN patients.

  GlobeNewswire Inc.
• Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

  Vera Therapeutics announced that it granted inducement awards, including stock options and restricted stock units, to its new Chief Operating Officer and ten new employees. The awards are intended to incentivize and retain the new hires.

  GlobeNewswire Inc.
• Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

  BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches.

  GlobeNewswire Inc.